Clinical Trial Update: A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy [Phase 1, Phase 2]

View source ↗

Summary

NaviFUS Corporation is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Epilepsy
• Focal Seizures
• Seizure Disorder

Drugs mentioned

• Low-intensity Focused Ultrasound Neuromodulation

Snippet

Sponsor: NaviFUS Corporation | Conditions: Drug Resistant Epilepsy, Epilepsy | Phase 1, Phase 2 | Status: RECRUITING